KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.90

Lidocaine for Neuropathic Cancer Pain (LiCPain): A Pilot Randomized Controlled Trial.

Jessica T Lee, Melanie R Lovell, Megan Ritchie, Belinda E Butcher, Caitlin Sheehan, Belinda Fazekas, Andrew McLachlan, Nikki McCaffrey, Jane L Phillips, Anthony Linton, Rajesh Aggarwal, Davinia Seah, Marian Kow, Rachel George, Richard Chye, Bev Noble, David Currow, Ghauri Aggarwal, Dipti Mittal, Chadi Ayoub, Eugenia Hutton, Angela Rao, Kat Urban, Priyanka Vandersman, Christine Sanderson, Meera Agar

J Pain Symptom Manage 70(3) 267-277.e6

PMID40466924
PMCID-
DOI10.1016/j.jpainsymman.2025.05.015
发表日期2025-06-04
入排依据:The study is a randomized, double-blind, placebo-controlled trial in humans with cancer pain, involving a drug intervention (lidocaine). However, it is a pilot/feasibility study (not a definitive Phase III/IIIb or Phase II/III trial), and its primary endpoint is pain intensity reduction, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it does not meet the eligibility criteria.
入排复审未纳入:The study is a randomized, double-blind, placebo-controlled trial in humans with cancer pain, involving a drug intervention (lidocaine). However, it is a pilot/feasibility study (not a definitive Phase III/IIIb or Phase II/III trial), and its primary endpoint is pain intensity reduction, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it does not meet the eligibility criteria.
摘要

摘要

CONTEXT: Extended continuous subcutaneous infusion of lidocaine for neuropathic cancer pain is currently used in clinical practice. OBJECTIVE: To determine the feasibility of conducting an adequately powered, multisite, double-blind, parallel group, titrated dose, randomized controlled trial of continuous subcutaneous infusion of lidocaine versus placebo in palliative care patients with neuropathic cancer pain. METHODS: Adults with neuropathic cancer pain were randomized to receive lidocaine hydrochloride 10%w/v (3000 mg/30 mL) diluted in sodium chloride 0.9% or sodium chloride 0.9% as a continuous subcutaneous infusion titrated daily for 72 hours. The dose increased from 1 to 2 mg/kg/h, capped at 120mg/hour (2800mg/day, rounded down). RESULTS: Seventeen participants were recruited over 54 months. There was a 93% [95%CI 88%-98%] completion rate of study medication and procedures meeting the predefined feasibility criteria. Eighty-eight percent of participants completed 72 hours of study medication. Treatment-emergent adverse events were infrequent and generally mild or moderate nervous system, cardiac and vascular abnormalities. There were no electrocardiogram abnormalities. Rapid titration from 1 to 2 mg/kg/h was tolerated. Both intervention and control groups demonstrated a reduction in pain intensity with no significant difference. CONCLUSION: This pilot demonstrates that a phase III clinical trial of extended continuous subcutaneous infusion of lidocaine for neuropathic cancer pain is feasible and provides important insights into modifications required to improve recruitment. Serum levels and relative safety suggest higher lidocaine doses could be cautiously evaluated. As the only prospective trial we are aware of to date, this trial informs clinical use of subcutaneous lidocaine infused over days.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。